PRA Expands Operations in Europe
PRA announces the expansion of operations in The Netherlands (NL) and the United Kingdom (UK) to accommodate staff growth and strong client demand for our Phase IIa-IIIB service offerings.
Located in the thriving city of Utrecht, NL, this new Dutch facility will host 20+ employees and is the first PRA office in that region to primarily support Product Registration trials. Staff from our three other NL locations (Groningen, Zuidlaren, and Assen) support early development and lab studies.
Previously, our Product Registration staff members in The Netherlands were either home-based or shared facilities with our Mechelen, Belgium employees. “But to better share best practices among employees, we felt that it was now necessary to provide a permanent office for the increasing Dutch Product Registration team,” said PRA’s Frank van de Wijngaert, Vice President and General Partner.
Also this month, PRA’s 240+ employees in Reading, UK relocated to a larger, PRA-designed facility that offers additional room for increasing headcounts and provides modern facilities for client and project team meetings. The location also offers a first-class business park environment with excellent transportation links.
Since 2009, PRA has opened nine new offices in Europe, demonstrating our commitment to meeting our clients’ diverse needs in a dynamic clinical trials environment.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Funding Cuts Threaten Diversity in Clinical Research
June 27th 2025In this video interview, Kyle McAllister, co-founder, CEO, Trially, discusses how recent federal funding cuts are likely to undermine research focused on underrepresented populations, and why long-term investment in community-based studies is essential to closing persistent health equity gaps.
